SREBP2 restricts osteoclast differentiation and activity by regulating IRF7 and limits inflammatory bone erosion

Abstract

Osteoclasts are multinucleated bone-resorbing cells, and their formation is tightly regulated to prevent excessive bone loss. However, the mechanisms by which osteoclast formation is restricted remain incompletely determined. Here, we found that sterol regulatory element binding protein 2 (SREBP2) functions as a negative regulator of osteoclast formation and inflammatory bone loss. Cholesterols and SREBP2, a key transcription factor for cholesterol biosynthesis, increased in the late phase of osteoclastogenesis. The ablation of SREBP2 in myeloid cells resulted in increased in vivo and in vitro osteoclastogenesis, leading to low bone mass. Moreover, deletion of SREBP2 accelerated inflammatory bone destruction in murine inflammatory osteolysis and arthritis models. SREBP2-mediated regulation of osteoclastogenesis is independent of its canonical function in cholesterol biosynthesis but is mediated, in part, by its downstream target, interferon regulatory factor 7 (IRF7). Taken together, our study highlights a previously undescribed role of the SREBP2-IRF7 regulatory circuit as a negative feedback loop in osteoclast differentiation and represents a novel mechanism to restrain pathological bone destruction.

References

[1] Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat. Rev. Immunol., 2019, 19: 626-642

[2] Park-Min KH. Mechanisms involved in normal and pathological osteoclastogenesis. Cell Mol. Life Sci., 2018, 75: 2519-2528

[3] Teitelbaum SL. Bone resorption by osteoclasts. Science, 2000, 289: 1504-1508

[4] Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology, 2000, 141: 3478-3484

[5] Luo J et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med, 2016, 22: 539-546

[6] Takayanagi H et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 2002, 416: 744-749

[7] Park-Min KH et al. IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J. Immunol., 2009, 183: 2444-2455

[8] Zhao B et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med, 2009, 15: 1066-1071

[9] Miyauchi Y et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J. Exp. Med, 2010, 207: 751-762

[10] Lee J et al. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood, 2006, 107: 2686-2693

[11] Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest, 2002, 109: 1125-1131

[12] Guo C et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity, 2018, 49: 842-856.e847

[13] Kusnadi A et al. The cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair. Immunity, 2019, 51: 241-257.e249

[14] Kim H, Oh B, Park-Min KH. Regulation of osteoclast differentiation and activity by lipid metabolism. Cells, 2021, 10: 89

[15] Inoue K, Imai Y. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim. Biophys. Acta, 2015, 1852: 2432-2441

[16] Jie Z et al. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis. Biochim. Biophys. Acta Mol. Basis Dis., 2019, 1865: 115-125

[17] Zheng ZG et al. Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice. Eur. J. Pharm., 2017, 809: 156-162

[18] Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol., 2012, 8: 656-664

[19] Merkel KD et al. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am. J. Pathol., 1999, 154: 203-210

[20] Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis. Front. Immunol., 2016, 7: 213

[21] Tang JJ et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab., 2011, 13: 44-56

[22] Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 1997, 89: 331-340

[23] Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol. Rev., 2005, 208: 181-193

[24] Takayanagi H et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 2000, 408: 600-605

[25] Ji JD et al. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J. Immunol., 2009, 183: 7223-7233

[26] Honda K et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature, 2005, 434: 772-777

[27] Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. J. Clin. Invest., 2017, 127: 2030-2039

[28] York AG et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell, 2015, 163: 1716-1729

[29] Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun., 2011, 12: 399-414

[30] Zhao Y et al. Overexpression of interferon regulatory factor 7 (irf7) reduces bone metastasis of prostate cancer cells in mice. Oncol. Res, 2017, 25: 511-522

[31] Bidwell BN et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med, 2012, 18: 1224-1231

[32] Place DE et al. Osteoclast fusion and bone loss are restricted by interferon inducible guanylate binding proteins. Nat. Commun., 2021, 12

[33] Ha H et al. Stimulation by TLR5 modulates osteoclast differentiation through STAT1/IFN-b. eta. J. Immunol., 2008, 180: 1382-1389

[34] Kwon JO et al. Haptoglobin acts as a TLR4 ligand to suppress osteoclastogenesis via the TLR4-IFN-beta Axis. J. Immunol., 2019, 202: 3359-3369

[35] Tang M, Tian L, Luo G, Yu X. Interferon-gamma-mediated osteoimmunology. Front. Immunol., 2018, 9: 1508

[36] Duque G et al. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J. Bone Min. Res, 2011, 26: 1472-1483

[37] MacLauchlan S et al. STING-dependent interferon signatures restrict osteoclast differentiation and bone loss in mice. Proc. Natl. Acad. Sci. USA, 2023, 120: e2210409120

[38] Assmann N et al. Srebp-controlled glucose metabolism is essential for NK cell functional responses. Nat. Immunol., 2017, 18: 1197-1206

[39] Bekkering S et al. Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell, 2018, 172: 135-146.e139

[40] Blanc M et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol., 2011, 9: e1000598

[41] Nakamura T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell, 2007, 130: 811-823

[42] Korganow AS et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity, 1999, 10: 451-461

[43] Bae S et al. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. J. Clin. Invest., 2017, 127: 2555-2568

[44] Bouxsein ML et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Min. Res, 2010, 25: 1468-1486

[45] Parfitt AM et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Min. Res, 1987, 2: 595-610

[46] Englen MD, Valdez YE, Lehnert NM, Lehnert BE. Granulocyte/macrophage colony-stimulating factor is expressed and secreted in cultures of murine L929 cells. J. Immunol. Methods, 1995, 184: 281-283

[47] Murata K et al. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity, 2017, 47: 66-79.e65

[48] Park-Min KH et al. Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat. Commun., 2014, 5

[49] Subramanian A et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA, 2005, 102: 15545-15550

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(AR069562)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Research Foundation of Korea (NRF)(2020R1A6A3A03037133)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)